Advertisement

In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat II. Vinblastine and Vincristine

  • X. J. Zhou
  • M. Martin
  • M. Placidi
  • J. P. Cano
  • R. Rahmani
Article

Summary

Vinblastine and Vincristine pharmacokinetics, including tissue distribution, metabolism and biliary excretion, were investigated, using both “in Vitro” and “in vivo” models, after i.v. injections in rats. Plasma kinetic curves were best fitted to a two-compartment open model. The average terminal half-lives of VLB and VCR were 14.3 h and 7.5 h, respectively. The systemic clearance and apparent distribution volume for VLB, respectively 1.49 l/h/kg and 11.46 l/kg, were significantly greater than those of VCR, 0.12.l/h/kg and 0.41 l/kg. VCR was found to be widely distributed in tissues after i.v. injections in rats.The highest drug accumulation site was the intestine (122.0 ng/g wet tissue at 24 h). Liver and kidneys also retained high proportions of drug (respectively, 47.0 ng/g and 44.4 ng/g at 24 h). Biliary excretion was more rapid for VCR (42.7% of total radioactivity excreted over 24 h) than VLB (28.2% of total dose over 24 h). For both molecules, the percentage of radioactivity excreted in bile over 30–48 h ranged between 40–50% of total dose. At high doses, either biliary excretion rate or cumulated excretion was reduced. High performance liquid chromatography analysis of bile samples revealed four biotransformation products for VLB and three for VCR. When incubated in freshly isolated rat hepatocytes, VLB penetrated more rapidly and intensely into the cells (more than 90% of total dose taken up over 20 min) than VCR (only about 40% accumulated), probably through a passive diffusion mechanism followed by tight cellular binding. “In vitro” metabolism patterns were similar to those found “in vivo”, except for the most polar metabolites observed “in vitro”. Two anti-Vinca monoclonal antibodies with different specificities were used to test VCR metabolite immunoreacttvities. The results suggested that some structural modifications occurred in the catharantine moiety of the molecule but that the dimeric structure seemed to be well conserved after biotransformation.

Key words

Vinblastine Vincristine distribution elimination metabolism hepatocytes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beer, C.T., Richards, J.F. (1964) The metabolisme of Vincaalkaloïds. The fate of tritiated vinblastine in rats. Lloydia, 27:352–360.Google Scholar
  2. 2.
    Berry, M.N., Friend, D.S. (1969) High-yield preparation of isolated rat liver parenchymal cells: A biochemical and fine structure study. J. cell. Biol., 43: 506–520CrossRefPubMedGoogle Scholar
  3. 3.
    Boston, R. G., Greif, P.C., Berman, M. (1981) Conversational-SAAM-an interactive program for kinetic analysis of biological systems. Comput. Prog. Biomed., 13: 111–115.CrossRefGoogle Scholar
  4. 4.
    Castle, M.C., Margileth, D.A., Olivierio, V.T. (1978) Distribution and excretion of [3H] Vincristine in the rat and the dog. Cancer Res., 36: 3684–3689Google Scholar
  5. 5.
    Culp, H.W., Daniels, W.D., McMahon, R.E. (1977) Distribution and tissue levels of [3H] vindesine in rats. Cancer Res., 37: 3053–3056.PubMedGoogle Scholar
  6. 6.
    Jackson, D.V., Sethi, V.S., Spurr C.K., White, D.R., Richards, F., Stuart, J.J., Murs, H.B., Cooper, M.R., Cartle, M.C. (1981) Pharmacokinetics of vincristine infusion. Cancer treat. Rep., 65: 1043–1048.PubMedGoogle Scholar
  7. 7.
    Nelson, R.L., Dyke, R.W., Root, M.A. (1980) Comparative pharmacokinetics of vindesine, vinblastine and vincristine in patients with cancer. Cancer treat. Rev., 7(suppl): 17–24.CrossRefPubMedGoogle Scholar
  8. 8.
    Owellen, R.J., Hartke, C.A., Dickerson, R.M., Hains, S.O. (1976) Inhibition of tubulin-Microtubule Polymerization by drugs of the vinca alkaloid class. Cancer Res., 36: 1499–1502.PubMedGoogle Scholar
  9. 9.
    Pontarotti, P.A., Rahmani, R., Martin, M., Barbet, J. (1985) Monoclonal antibodies to antitumor Vinca alkaloïds: thermodynamics and kinetics. Molec. Immunol., 22:277–284.CrossRefGoogle Scholar
  10. 10.
    Ratrin, M.J., Vogelzang, N.J., Sinkule, J.A. (1987) Interpatient and Intrapatient variability in vinblastine pharmacokinetics. Clin. Pharmacol. Ther., 41: 61–67.Google Scholar
  11. 11.
    Rahmani, R., Barbet, J., Cano, J.P.A (1983) 125I radiolabeled probe for vinblastine and vincristine radioimmunoassays. Clin. Chim. Acta, 129:57–69.CrossRefPubMedGoogle Scholar
  12. 12.
    Rahmani, R., Bruno, R., Iliadis, A., Favre, R., Just, S., Barbet, J., Cano J.P. (1987) Clinical pharmacokinetics of the antitumor drugs navelbine. Cancer Res. 47:3796–5799.Google Scholar
  13. 13.
    Rahmani, R., Guéritte, F., Martin, M., Jurt, S., Cano, J.P., Barbet, J. (1986) Comparative pharmacokinetics of antitumor Vincaalkaloïds: intravenous bolus injections of navelbine and related alkaloïds to cancer patients and rats. Cancer Chemoter. Pharmacol., 16:223–228.CrossRefGoogle Scholar
  14. 14.
    Rahmani, R., Martin, M., Kleisbauer J.P., Cano, J.P., Barbet, J. (1985) Clinical Pharmacokinetics of Vindesine infusion. Cancer Treat. Rep., 69:839–844.PubMedGoogle Scholar
  15. 15.
    Rahmani, R., Martin, M., Favre, R., Cano, J.P., Barbet, J. (1985) Clinical pharmacokinetics of Vindesine: repeated treatment by intravenous bolus injections. Eur. J. Cancer Clin. Oncol., 2:1409–1417.Google Scholar
  16. 16.
    Roots, M.A., Gerzon, K., Dyke, R.W. (1975) A radioimmunoassay for Vinblastine and vincristine. In second National Meeting of the Federation of analytical Chemistry and Sepectroscopy Societies, Indianap olis, Ind, P. 125.Google Scholar
  17. 17.
    Young, J.A., Howell, S.B., Green, M.R. (1984) Pharmacokinetics and toxicity of five-day continuous infusion of Vinblastine. Cancer Chemoter. Pharmacol., 12:43–45.Google Scholar
  18. 18.
    Vin den Berg, H.W., Desai, Z.R., Wilson, R., Kennedy, G., Bridges, J.M., Shanks, R.G. (1982) The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline pho sphatase and dose-limited elimination. Cancer Chemoter. Pharmacol., 8: 219–227.Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • X. J. Zhou
    • 1
  • M. Martin
    • 1
  • M. Placidi
    • 1
  • J. P. Cano
    • 1
  • R. Rahmani
    • 1
  1. 1.INSERM U-278Faculté de PharmacieMarseille Cedex 5France

Personalised recommendations